Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.

Chen KTJ, Anantha M, Leung AWY, Kulkarni JA, Militao GGC, Wehbe M, Sutherland B, Cullis PR, Bally MB.

Drug Deliv Transl Res. 2019 Sep 3. doi: 10.1007/s13346-019-00674-7. [Epub ahead of print]

PMID:
31482519
2.

A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.

Wehbe M, Malhotra A, Anantha M, Roosendaal J, Leung AWY, Plackett D, Edwards K, Gilabert-Oriol R, Bally MB.

J Control Release. 2017 Apr 28;252:50-61. doi: 10.1016/j.jconrel.2017.03.010. Epub 2017 Mar 10.

3.

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.

Wehbe M, Anantha M, Shi M, Leung AW, Dragowska WH, Sanche L, Bally MB.

Int J Nanomedicine. 2017 May 31;12:4129-4146. doi: 10.2147/IJN.S137347. eCollection 2017.

4.

Optimization of liposomal topotecan for use in treating neuroblastoma.

Chernov L, Deyell RJ, Anantha M, Dos Santos N, Gilabert-Oriol R, Bally MB.

Cancer Med. 2017 Jun;6(6):1240-1254. doi: 10.1002/cam4.1083. Epub 2017 May 23.

5.

A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.

Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M.

Eur J Pharm Biopharm. 2008 Mar;68(3):607-17. Epub 2007 Sep 2.

PMID:
17904831
6.

Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.

Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, Karlsson G, Bally MB.

J Control Release. 2011 Mar 10;150(2):212-9. doi: 10.1016/j.jconrel.2010.11.018. Epub 2010 Nov 19.

PMID:
21094191
7.

Development of a copper-clioquinol formulation suitable for intravenous use.

Wehbe M, Malhotra AK, Anantha M, Lo C, Dragowska WH, Dos Santos N, Bally MB.

Drug Deliv Transl Res. 2018 Feb;8(1):239-251. doi: 10.1007/s13346-017-0455-7.

8.

Intracellular ROS protection efficiency and free radical-scavenging activity of quercetin and quercetin-encapsulated liposomes.

Rezaei-Sadabady R, Eidi A, Zarghami N, Barzegar A.

Artif Cells Nanomed Biotechnol. 2016;44(1):128-34. doi: 10.3109/21691401.2014.926456. Epub 2014 Jun 24.

PMID:
24959911
9.

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD.

Biochim Biophys Acta. 2007 Mar;1768(3):678-87. Epub 2006 Dec 6.

10.

Copper-topotecan complexation mediates drug accumulation into liposomes.

Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB.

J Control Release. 2006 Aug 10;114(1):78-88. Epub 2006 Jun 2.

PMID:
16842880
11.

Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.

Tang WL, Tang WH, Chen WC, Diako C, Ross CF, Li SD.

Mol Pharm. 2017 Jun 5;14(6):1969-1979. doi: 10.1021/acs.molpharmaceut.7b00077. Epub 2017 May 9.

PMID:
28460165
12.
13.
14.

Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.

Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M, Carminati P, Luisi PL.

J Liposome Res. 2004;14(1-2):87-109.

PMID:
15461935
15.

Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB.

Clin Cancer Res. 2004 Oct 1;10(19):6638-49.

16.

Double loading of cyclosporine A in liposomes using cyclodextrin complexes.

Malaekeh-Nikouei B, Davies N.

PDA J Pharm Sci Technol. 2009 Mar-Apr;63(2):139-48.

PMID:
19634352
17.

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development.

Wehbe M, Anantha M, Backstrom I, Leung A, Chen K, Malhotra A, Edwards K, Bally MB.

PLoS One. 2016 Apr 7;11(4):e0153416. doi: 10.1371/journal.pone.0153416. eCollection 2016.

18.

A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.

Farzaneh H, Ebrahimi Nik M, Mashreghi M, Saberi Z, Jaafari MR, Teymouri M.

Int J Pharm. 2018 Nov 15;551(1-2):300-308. doi: 10.1016/j.ijpharm.2018.09.047. Epub 2018 Sep 20.

PMID:
30243944
19.

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.

Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB.

Invest New Drugs. 2013 Feb;31(1):46-58. doi: 10.1007/s10637-012-9832-8. Epub 2012 May 22.

PMID:
22615060
20.

Physicochemical characterization of dual action liposomal formulations: anticancer and antimicrobial.

Das A, Konyak PM, Das A, Dey SK, Saha C.

Heliyon. 2019 Aug 27;5(8):e02372. doi: 10.1016/j.heliyon.2019.e02372. eCollection 2019 Aug.

Supplemental Content

Support Center